Foxo Technologies (FOXO) investor relations material

Executive summary

• Net revenues increased 63% year-over-year to $5.2 million for Q1 2026, driven by growth in the Healthcare segment and the acquisition of Vector in Life Science Services.

• Loss from operations improved to $(0.3) million from $(1.5) million year-over-year, but net loss attributable to common stockholders was $(1.5) million, up from $(0.8) million, due to the absence of a prior year one-time gain.

• Working capital deficit stood at $27.1 million as of March 31, 2026, with cash and cash equivalents of $65,896.

• The company continues to face substantial doubt about its ability to continue as a going concern without additional financing.

Financial highlights

• Net revenues: $5.2 million (Q1 2026) vs. $3.2 million (Q1 2025), a $2.0 million increase.

• Direct costs of revenues: $2.5 million (49% of net revenues), up from $1.9 million (60%).

• Operating expenses: $5.4 million, up 15% year-over-year.

• Net loss attributable to FOXO: $(1.5) million (Q1 2026) vs. $(0.6) million (Q1 2025).

• Adjusted EBITDA: $(0.4) million (Q1 2026) vs. $(1.7) million (Q1 2025).

Outlook and guidance

• Management expects continued losses and negative cash flow until additional capital is secured and operations scale.

• The inability to complete a reverse stock split due to FINRA denial may limit access to capital and adversely affect liquidity.